


PRODUCT INFORMATION



LY341495

Item No. 14693

CAS Registry No.: 201943-63-7
Formal Name: αS-amino-α-[(1S,2S)-2-carboxycyclopropyl]-9H-xanthene-9-propanoic acid
MF: C₂₀H₁₉NO₅
FW: 353.4
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years
Special Conditions: Gentle warming is required when dissolving in DMSO



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LY341495 is supplied as a crystalline solid. A stock solution may be made by dissolving the LY341495 in the solvent of choice, which should be purged with an inert gas. LY341495 is soluble in organic solvents such as DMSO and methanol. The solubility of LY341495 in these solvents is approximately 0.5 and 0.1 mg/ml, respectively.

Description

LY341495 is a potent and selective antagonist of the group II metabotropic glutamate receptors (mGluR), mGluR2 and mGluR3 (IC₅₀s = 21 and 14 nM, respectively, for human isoforms).¹⁻³ It less effectively blocks mGluR8 and mGluR7 (IC₅₀s = 173 and 990 nM, respectively) and weakly antagonizes mGluR1, mGluR5, and mGluR4 (IC₅₀s = 6.8, 8.2, and 22 μM, respectively).² In rat forebrain tissue, LY341495 may bind mGluR3 more avidly than mGluR2.⁴ LY341495 can be effectively used in isolated cells, tissues, and *in vivo*.⁴⁻⁶ In mice, it penetrates the blood-brain barrier and has been used to study the roles of mGlu2/3 receptors in the brain.^{5,7,8}

References

1. Collado, I., Ezguerra, J., Mazón, A., *et al. Bioorg. Med. Chem. Lett.* **8(20)**, 2849-2854 (1998).
2. Kingston, A.E., Ornstein, P.L., Wright, R.A., *et al. Neuropharmacology* **37(1)**, 1-12 (1998).
3. Bräuner-Osborne, H., Egebjerg, J., Nielsen, E.O., *et al. J. Med. Chem.* **43(14)**, 2609-2645 (2000).
4. Wright, R.A., Arnold, M.B., Wheeler, W.J., *et al. J. Pharmacol. Exp. Ther.* **298(2)**, 453-460 (2001).
5. Battaglia, G., Busceti, C.L., Pontarelli, F., *et al. Neuropharmacology* **45(2)**, 155-166 (2003).
6. Fitzjohn, S.M., Bortolotto, Z.A., Palmer, M.J., *et al. Neuropharmacology* **37(12)**, 144-1458 (1998).
7. Benneyworth, M.A., Xiang, Z., Smith, R.L., *et al. Mol. Pharmacol.* **72(2)**, 477-484 (2007).
8. Galici, R., Jones, C.K., Hemstapat, K., *et al. J. Pharmacol. Exp. Ther.* **318(1)**, 173-185 (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM